Treatment Approaches for Actinic Keratosis

Maud H. E. Jansen; Nicole W. J. Kelleners-Smeets; Klara Mosterd

doi:10.1056/NEJMc1904535

Treatment Approaches for Actinic Keratosis

Maud H. E. Jansen^*, Nicole W. J. Kelleners-Smeets, Klara Mosterd

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Citation (Web of Science)

25 Downloads (Pure)

Original language	English
Pages (from-to)	2275-2276
Number of pages	2
Journal	New England Journal of Medicine
Volume	380
Issue number	23
DOIs	https://doi.org/10.1056/NEJMc1904535
Publication status	Published - 6 Jun 2019

Access to Document

10.1056/NEJMc1904535

Full text Final published version, 64.5 KBLicence: Taverne

Cite this

@article{35d5dab9300148e6823a85265ed0b0f1,

title = "Treatment Approaches for Actinic Keratosis",

author = "Jansen, {Maud H. E.} and Kelleners-Smeets, {Nicole W. J.} and Klara Mosterd",

note = "Funding Information: Dr. van Vollenhoven reports receiving consulting fees from AbbVie, AstraZeneca, Biogen, Biotest (Germany), Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead Sciences, Janssen, Novartis, Pfizer, Servier, and UCB, speaker{\textquoteright}s fees from AbbVie, AstraZeneca, Eli Lilly, Janssen, Pfizer, and UCB, and research funding from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and UCB; and Dr. Nurmohamed, receiving consulting fees from AbbVie, Cel-gene, Celltrion, Eli Lilly, Janssen, and Sanofi, speaker{\textquoteright}s fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Roche, and Sanofi, and research funding from AbbVie, Bristol-Myers Squibb, Cel-gene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche, and Sanofi. No other potential conflict of interest relevant to this letter was reported.",

year = "2019",

month = jun,

day = "6",

doi = "10.1056/NEJMc1904535",

language = "English",

volume = "380",

pages = "2275--2276",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "MASSACHUSETTS MEDICAL SOCIETY",

number = "23",

}

TY - JOUR

T1 - Treatment Approaches for Actinic Keratosis

AU - Jansen, Maud H. E.

AU - Kelleners-Smeets, Nicole W. J.

AU - Mosterd, Klara

N1 - Funding Information: Dr. van Vollenhoven reports receiving consulting fees from AbbVie, AstraZeneca, Biogen, Biotest (Germany), Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead Sciences, Janssen, Novartis, Pfizer, Servier, and UCB, speaker’s fees from AbbVie, AstraZeneca, Eli Lilly, Janssen, Pfizer, and UCB, and research funding from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and UCB; and Dr. Nurmohamed, receiving consulting fees from AbbVie, Cel-gene, Celltrion, Eli Lilly, Janssen, and Sanofi, speaker’s fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Roche, and Sanofi, and research funding from AbbVie, Bristol-Myers Squibb, Cel-gene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche, and Sanofi. No other potential conflict of interest relevant to this letter was reported.

PY - 2019/6/6

Y1 - 2019/6/6

U2 - 10.1056/NEJMc1904535

DO - 10.1056/NEJMc1904535

M3 - Comment/Letter to the editor

SN - 0028-4793

VL - 380

SP - 2275

EP - 2276

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 23

ER -